75 related articles for article (PubMed ID: 8302686)
1. Comparison of the pharmacokinetic and pharmacodynamic activity of piperacillin and mezlocillin.
Sullivan MC; Nightingale CH; Quintiliani R; Sweeney K
Pharmacotherapy; 1993; 13(6):607-12. PubMed ID: 8302686
[TBL] [Abstract][Full Text] [Related]
2. Use of pharmacodynamic concepts in developing a cost-effective dosing method for piperacillin.
Quintiliani R; Nightingale CH; Sullivan MC
Clin Ther; 1993; 15 Suppl A():44-9. PubMed ID: 8513461
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
Frei CR; Burgess DS
Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
[TBL] [Abstract][Full Text] [Related]
5. Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
Downs JT; Andriole VT; Ryan JL
Yale J Biol Med; 1986; 59(1):11-6. PubMed ID: 3634545
[TBL] [Abstract][Full Text] [Related]
6. [The effect of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime].
Bauernfeind A; Grimm H; Klietmann W; Opferkuch W; Werner H
Arzneimittelforschung; 1991 Aug; 41(8):831-8. PubMed ID: 1781806
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
Schmalreck AF; Wildfeuer A
Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
[TBL] [Abstract][Full Text] [Related]
8. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro susceptibilities among gram-negative rods.
Westblom TU; Midkiff BR
W V Med J; 1989 Jul; 85(7):279-80. PubMed ID: 2756707
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of azlocillin, carbenicillin, mezlocillin and piperacillin against Pseudomonas aeruginosa.
Høiby N; Bremmelgaard A; Schouenborg P
Scand J Infect Dis Suppl; 1981; 29():27-30. PubMed ID: 6458882
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
Langgartner J; Lehn N; Glück T; Herzig H; Kees F
Chemotherapy; 2007; 53(5):370-7. PubMed ID: 17785973
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal activity and killing rate of serum in volunteers receiving pefloxacin alone or in combination with ceftazidime, piperacillin or mezlocillin against Pseudomonas aeruginosa.
Van der Auwera P; Husson M; Klastersky J
J Antimicrob Chemother; 1988 Jan; 21(1):49-55. PubMed ID: 3128521
[TBL] [Abstract][Full Text] [Related]
13. [In vitro effect of piperacillin on aerobic bacteria. Variations according to the phenotypes of resistance to beta-lactam antibiotics].
Jarlier V; Soussy CJ; Chanal M; Sirot D; Le Van Thoi J; Bismuth R; Grosset J; Duval J; Cluzel R
Presse Med; 1986 Dec; 15(46):2272-8. PubMed ID: 2949267
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity.
Hardin TC; Butler SC; Ross S; Wakeford JH; Jorgensen JH
Pharmacotherapy; 1994; 14(2):147-52. PubMed ID: 8197032
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics and serum bactericidal activity of mezlocillin, ticarcillin and piperacillin, with and without gentamicin.
Viollier AF; Standiford HC; Drusano GL; Tatem BA; Moody MR; Schimpff SC
J Antimicrob Chemother; 1985 May; 15(5):597-606. PubMed ID: 4008387
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa.
Greenberg RN; Bollinger MR; Alivisatos MR
Clin Ther; 1986; 8(6):655-7. PubMed ID: 3098426
[TBL] [Abstract][Full Text] [Related]
17. [Bactericidal and potent antiadhesive activity of sulbenicillin].
Amato G; Nani E; Covelli B; Mattina R; Cocuzza G; Pappalardo C; Chisari G; Lo Bue AM; Gismondo MR; Nicoletti G
G Batteriol Virol Immunol; 1986; 79(7-12):204-15. PubMed ID: 3135222
[TBL] [Abstract][Full Text] [Related]
18. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis.
Zeitlinger MA; Erovic BM; Sauermann R; Georgopoulos A; Müller M; Joukhadar C
J Antimicrob Chemother; 2005 Oct; 56(4):703-8. PubMed ID: 16120628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
